bictegravir (Biktarvy) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT DrugBank PubChem

Active Ingredient History

NOW
  • Now
Bictegravir is a component of the fixed-dose combination product bictegravir/emtricitabine/tenofovir alafenamide (BIKTARVY®), which received marketing approval for the treatment of human immunodeficiency virus (HIV) infection by the U.S. Food and Drug Administration in February 2018. Bictegravir inhibits the strand transfer activity of HIV-1 integrase, an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the virus.   NCATS

Chemistry

  • SMILES: O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2
  • InChIKey: SOLUWJRYJLAZCX-LYOVBCGYSA-N
  • Mol. Mass: 449.39
  • ALogP: 1.63
  • ChEMBL Molecules:
    bictegravir  
    bictegravir sodium  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

bictegravir | gs-9883

Organizations (81)

Research & Development (81)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (32)

Approved Indications (1)


 

HIV Infections

Experimental Indications - Clinical Trial Phases 1-4 (32)


 

Alveolar Bone Loss (Phase 4)

Antiretroviral Therapy, Highly Active (Phase 4)

Art (Phase 4)

Body Weight Changes (Phase 3)

Bone Diseases, Metabolic (Phase 4)

Buprenorphine (Phase 4)

Coinfection (Phase 4)

Coronary Artery Disease (Phase 4)

Drug Misuse (Phase 4)

Fasting (Phase 3)

Harm Reduction (Phase 4)

Healthy Volunteers (Phase 1)

Hepatitis B (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV Infections ()

HIV Seropositivity (Phase 3)

Kidney Transplantation (Phase 4)

Medication Adherence (Phase 3)

Metabolic Syndrome (Phase 3)

Methadone (Phase 4)

Minority Health (Phase 3)

Obesity (Phase 4)

Opioid-Related Disorders (Phase 4)

Pre-Exposure Prophylaxis (Phase 3)

Sexually Transmitted Diseases (Phase 4)

Transsexualism (Phase 4)

Treatment Adherence and Compliance (Phase 3)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 83
  • # of Trial Organizations: 81

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue